Skip to main content

Scott Kathleen D.

In the past year, 1 open-market sale filing worth $13.09 and no purchases.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
$13.09
1 filing
Net
−$13.09
Bought minus sold
Companies
1
With open-market trades

Trades

Every Form 4 that lists Scott Kathleen D. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

DRMA Dermata Therapeutics, Inc.

Director1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 16, 2026 (view filing)Jun 16Same dayScott Kathleen D.DirectorSSale−11$1.19−$13.09−100.0%0 after

SPRY ARS Pharmaceuticals, Inc.

Chief Financial Officer5 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 22, 2025 (view filing)Aug 211 dayScott Kathleen D.Chief Financial OfficerSSale−12.5K$15.00−$187.5K−55.5%10.0K after10b5-1
May 22, 2025 (view filing)May 202 daysScott Kathleen D.Chief Financial OfficerSSale−50.0K$14.10−$705.0K−87.1%7.42K after
Oct 17, 2024 (view filing)Oct 161 dayScott Kathleen D.Chief Financial OfficerSSale−12.5K$16.00−$200.0K−71.6%4.95K after10b5-1
Aug 21, 2024 (view filing)Aug 201 dayScott Kathleen D.Chief Financial OfficerSSale−12.5K$16.00−$200.0K−48.6%13.2K after10b5-1
Dec 1, 2022 (view filing)Nov 292 daysScott Kathleen D.Chief Financial OfficerPPurchase+8.25K$6.24+$51.5KNew position8.25K after